NCT00321724View on ClinicalTrials.gov

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 31, 2007

Conditions
B-cell Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
Interventions
DRUG

cediranib maleate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00321724 - AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter